Combination Paclitaxel, Carboplatin and Temozolomide

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Lung DiseasesCancer
Interventions
DRUG

Combination Treatment - Cohort 1

"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 75 mg/m2 per day from day 2 to day 6."

DRUG

Combination Treatment - Cohort 2

"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 100 mg/m2 per day from day 2 to day 6."

DRUG

Combination Treatment - Cohort 3

"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 125 mg/m2 per day from day 2 to day 6."

DRUG

Combination Treatment - Cohort 4

"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 150 mg/m2 per day from day 2 to day 6."

Trial Locations (1)

87106

University of New Mexico Cancer Center, Albuquerque

All Listed Sponsors
lead

New Mexico Cancer Research Alliance

OTHER

NCT00249964 - Combination Paclitaxel, Carboplatin and Temozolomide | Biotech Hunter | Biotech Hunter